| Balance Sheets | 2026-06-30 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 540,515 | |||
| Prepaid expenses and other current assets | 3,073 | |||
| Total current assets | 543,588 | |||
| Other assets, noncurrent | 48 | |||
| Total assets | 543,636 | |||
| Accounts payable | 3,482 | |||
| Accrued expenses and other current liabilities | 8,879 | |||
| Paramora warrant obligation | 9,527 | |||
| Related party accounts payable and other current liabilities | 5,662 | |||
| Total current liabilities | 27,550 | |||
| Other liabilities, noncurrent | 27 | |||
| Total liabilities | 27,577 | |||
| Preferred stock, value-Series BNon Voting Convertible Preferred Stock | 117,621 | |||
| Preferred stock, value-Series CNon Voting Convertible Preferred Stock | 12,376 | |||
| Common stock, par value of 0.00001 per share 500,000,000 shares authorized at june 30, 2026 and 300,000,000 shares authorized at december 31, 2025 61,734,601 and 1,597,321 shares issued and outstanding at june 30, 2026 and december 31, 2025, respectively | 1 | |||
| Additional paid-in capital | 931,649 | |||
| Accumulated deficit | -546,320 | |||
| Accumulated other comprehensive income | 732 | |||
| Total stockholders equity | 516,059 | |||
| Total liabilities and stockholders equity | 543,636 | |||
Damora Therapeutics, Inc. (DMRA)
Damora Therapeutics, Inc. (DMRA)